Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Gender Discrimination Class Action Alleges Maternity Leave Leads To Manager Pay Cuts

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck is the sixth pharmaceutical company to be hit with a sales rep gender discrimination class action by Sanford Heisler; similar complaints have survived motions to dismiss filed in wake of Supreme Court’s Wal-Mart v. Dukes ruling.

You may also be interested in...



Gender Discrimination Suits: Cases Against Pharma Continue Even As Payouts Slow

Novartis will pay $8m to settle second case; last year Daiichi Sankyo settled gender discrimination class action for the same amount and action against Bayer was dismissed following confidential resolution. Cases are ongoing against Merck and Forest.

Forest Gender Discrimination Suit Cites “Striking” Similarities With Other Firms

Forest is the fourth pharmaceutical company to face a sales rep gender discrimination class action by Sanford Wittels & Heisler; complaint seeks $100 million in damage as well as changes in pay and promotion.

Supreme Court's Wal-Mart Ruling Could Curtail Pharma Gender Discrimination Cases

The attorneys who won a gender discrimination suit against Novartis Pharmaceuticals Corp. said they would have had a tough time prevailing if they'd gone to court after the Supreme Court's ruling in the Wal-Mart gender discrimination class action.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS075795

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel